乳腺癌高危因素和预后的研究进展

张月君 已出版文章查询
张月君
本平台内已出版文章查询
1

+ 作者地址

1230022,合肥,安徽医科大学第一附属医院乳腺外科


0
  • 摘要
  • 参考文献
  • 相关文章
  • 统计
乳腺癌的发病率逐年上升,远处转移是导致患者不良预后的主要原因.目前关于乳腺癌预后相关危险因素已成为研究的一个热点,因此准确判断乳腺癌高危因素有利于指导临床治疗、判断预后及临床疗效评价.

[1] Tsutsui S;Kume M;Era S .Prognostic value of microvessel density in invasive ductal carcinoma of the breast.[J].Breast cancer: the journal of the Japanese Breast Cancer Society,2003(4):312-319.

[2] Colditz GA;Rosner BA;Chen WY;Holmes MD;Hankinson SE .Risk factors for breast cancer according to estrogen and progesterone receptor status.[J].Journal of the National Cancer Institute,2004(3):218-228.

[3] Silva JM;Dominguez G;Silva J et al.Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics[J].Clinical Cancer Research,2001,7(09):2821-2825.

[4] Peck,K;Sher,YP;Shih,JY;Roffler,SR;Wu,CW;Yang,PC .Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients.[J].Cancer research,1998(13):2761-2765.

[5] Kahn HJ;Yang LY;Blondal J;Lickley L;Holloway C;Hanna W;Narod S;McCready DR;Seth A;Marks A .RT-PCR amplification of CK19 mRNA in the blood of breast cancer patients: correlation with established prognostic parameters.[J].Breast cancer research and treatment,2000(2):143-151.

[6] Porter PL;Malone KE;Heagerty PJ et al.Expression of cell-cycle regulators p27Kipl and cyclin E,alone and in combination,correlate with survival in young breast cancer patients[J].Nature Medicine,1997,3(02):222-225.

[7] Donnellan R;Kleinschmidt I;Chetty R;Cyclin E .immunoexpression in breast ductal carcinoma:pathologic correlations and prognostic implications[J].Human Pathology,2001,32(01):89-94.

[8] Keyomarsi K;Tucker SL;Buchholz TA;Callister M;Ding Y;Hortobagyi GN;Bedrosian I;Knickerbocker C;Toyofuku W;Lowe M;Herliczek TW;Bacus SS .Cyclin E and survival in patients with breast cancer.[J].The New England journal of medicine,2002(20):1566-1575.

[9] Han S;Park K;Bae BN;Kim KH;Kim HJ;Kim YD;Kim HY .Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer.[J].Journal of Surgical Oncology,2003(4):241-247.

[10] Rudolph P;Kuhling H;Alm P;Ferno M;Baldetorp B;Olsson H;Parwaresch R .Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer.[J].International Journal of Cancer,2003(5):674-680.

[11] Span PN;Tjan Heijnen VC;Manders P;Beex LV;Sweep CG .Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer.[J].Oncogene,2003(31):4898-4904.

[12] Aklis S;Keyomarsi K .Low-molecular-weight cyclin E:the missing link between biology and clinical outcome[J].Breast Cancer Research,2004,6(05):188-191.

[13] O'Brien N;Maguire TM;0' Donovan N et al.Mammaglobin a:a promising marker for breast cancer[J].Clinical Chemistry,2002,48(08):1362-1364.

[14] Un YC;Wu Chou YH;Liao 1C et al.The expression of mammaglobin mRNA in peripheral blood of metastatic breast cancer patients as an adjunct to serum tumor markers[J].Cancer Letters,2003,191(01):93-99.

[15] Ooka M;Tamaki Y;Sakita I;Fujiwara Y;Yamamoto H;Miyake Y;Sekimoto M;Ohue M;Sugita Y;Miyoshi Y;Ikeda N;Noguchi S;Monden M .Bone marrow micrometastases detected by RT-PCR for mammaglobin can be an alternative prognostic factor of breast cancer.[J].Breast cancer research and treatment,2001(2):169-175.

[16] Ferrucci PF;Rabascio C;Gigli F;Corsini C;Giordano G;Bertolini F;Martinelli G .A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer.[J].International journal of oncology,2007(4):955-962.

[17] Jukkola A;Bloigu R;Soini Y et al.c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease[J].EUROPEAN JOURNAL OF CANCER,2001,37(03):347-354.

[18] Schippinger W;Regitnig P;Bauerahofer T et al.The course of serum HER-2/neu levels as an independent prognostic factor for survival in metaslatic breast cancer[J].Oncology Reports,2004,11(06):1331-1336.

[19] Vera-Roman JM;Rubio-Martinez LA .Comparative assays for theHER-2/neu oncogene status in breast cancer[J].Archives of Pathology and Laboratory Medicine,2004,128(06):627-363.

[20] 张瑰红,杨文涛,周晓燕,曾郁,陆洪芬,施达仁.人表皮生长因子受体-2基因与乳腺癌患者淋巴管新生的相关性及其对预后的影响[J].中华医学杂志,2007(03):155-160.

[21] Rahko E;Blanco G;Soini Y et al.A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients[J].European Journal of Cancer,2003,39(04):447-453.

[22] Bernard Gallon DJ;Dechelotte PJ;Le Corre L;Vissac Sabatier C;Favy DA;Cravello L;De Latour MP;Bignon YJ .Expression of BRCA1 and BRCA2 in male breast cancers and gynecomastias.[J].Anticancer Research: International Journal of Cancer Research and Treatment,2003(1B):661-667.

[23] Greggi S;Scala F;Laurelli G .Hereditary breast and ovarian cancer[J].Current Problems in Cancer,2003,27(01):24-28.

[24] Comings DE;Gade Andavolu R;Cone LA;Muhleman D;MacMurray JP .A multigene test for the risk of sporadic breast carcinoma.[J].Cancer,2003(9):2160-2170.

[25] King MC;Marks JH;Mandell JB et al.Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2[J].Science,2003,302(5645):643-646.



期刊热词
  • + 更多
  • 字体大小